Eladocagene Exuparvovec for Aromatic L-Amino Acid Decarboxylase Deficiency
This JAMA Insights discusses the US Food and Drug Administration approval of Kebilidi, eladocagene exuparvovec, for the treatment of aromatic L-amino acid decarboxylase deficiency in adult and pediatric patients.
Authors
- SoJeong Yi (ORCID: https://orcid.org/0000-0001-6659-1585)
- Lola A. Fashoyin‐Aje (ORCID: https://orcid.org/0000-0001-7328-7813)
- Avanti Golikeri
Institutions
- Center for Biologics Evaluation and Research (US)
- United States Food and Drug Administration (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1001/jama.2024.28666
- Citations
- 6
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 7.91